Navigation Links
New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Date:5/11/2012

SAN ANTONIO, May 10, 2012 /PRNewswire-iReach/ -- Electrochemical Oxygen Concepts (EO2™ Concepts), the developer of a unique and innovative chronic wound treatment device, announced it has been added to Marathon Medical's (Commerce City, CO) existing Federal Supply Schedule (FSS) contract, administered by The Department of Veterans Affairs (VA). The TransCu O2®, a noninvasive, electrochemical low-dose tissue oxygenation system for the treatment of difficult-to-heal wounds, is now available to all organizations that purchase from the FSS including the entire federal healthcare system, the largest healthcare provider in the United States with more than 1,300 Veterans health facilities, Department of Defense medical treatment facilities, Military Hospitals, and Indian Health Service Hospitals.

(Photo:  http://photos.prnewswire.com/prnh/20120510/CG05448)

EO2™ Concepts is a privately held, advanced wound care technology company whose flagship product, the TransCu O2®, is an FDA cleared Class III medical device.  The company's President Joe Moffett says that he believes the TransCu O2® can revolutionize the treatment of chronic and difficult-to-heal wounds for veterans and others who suffer from these painful and costly wounds.

"Our team is honored to partner with the Department of Veterans Affairs to provide a state-of-the-art wound care therapy for our country's military veterans," said Moffett.  "The portable treatment is simple, can be delivered in the home environment and supports a more normal quality of life – even while receiving the treatment.  We believe that the TransCu O2® will transform the current treatment of wound care and make a contribution to lowering costs within our healthcare system."

The TransCu O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-flow pure oxygen to treat a variety of lower limb wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds, yet current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCu O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring with automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

Chronic lower limb wounds are a complex problem and a leading cause of disability. These wounds impact overall disease burden, quality of life, activities of daily living, and healthcare costs for thousands of Veterans.  The Continuous Diffusion of Oxygen therapy provided by the TransCu O2 has demonstrated improved patient outcomes with shorter healing times while bettering the patient's quality of life.  These advanced medical outcomes can subsequently lower costs to treat difficult-to-heal wounds.

About Marathon Medical:

Marathon Medical is dedicated to providing the highest quality products and services at competitive prices creating the best value for its customers. They serve the healthcare industry nationwide with products and services that help hospitals and pharmacies reduce costs, improve productivity and deliver better care to patients. Marathon Medical salutes the contracting officers, administration personnel, nurses and doctors who take care of this nation's heroes. They work diligently in concert with the contracting officers to combine excellent products with competitive pricing to bring the greatest value to the veteran patient.

About Electrochemical Oxygen Concepts (EO2™ Concepts):

EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  For more information, please visit www.eo2concepts.com

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV
3. Bioness Initiates Study of Neuromodulation System for Chronic Peripheral Nerve Pain
4. Argon Medical Devices Announces The Launch of a Unique New Chronic Hemodialysis Catheter
5. Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
6. Biovista Awarded Research Grant on Chronic Fatigue Syndrome From the CFIDS Association of America
7. Silver Hill Hospital, Nationally Recognized Psychiatric Institution Opens Groundbreaking Chronic Pain and Addiction Treatment Center
8. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
9. ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients
10. Accident Fund Holdings, Inc. Launches Narcotics Program to Protect Injured Workers from Drugs Used to Manage Chronic Pain
11. Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... pleased to announce that 12 scientific abstracts have been accepted ... Epilepsy Society (AES) Annual Meeting, which takes place from 2-6 ... Data being presented include posters further ... (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. 2,3,4,6,8 ... the union of epilepsy care and antiepileptic drugs in the ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... MedCore" report to their offering. ... , The cerebrospinal fluid (CSF) ... individuals, it is circulated though the brain and its ventricles, the spine ... CSF surrounding the brain changes significantly. As a ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announced today that it has raised $6.0 million in an initial round of ... Health’s conviction that patients and their caregivers can receive far better care through ...
(Date:12/2/2016)... Grants Pass, OR (PRWEB) , ... December 02, ... ... Daryl Wein, Medical Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The ... and host of The Sharon Kleyne Hour Power of Water, Global Climate Change ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... offer a comprehensive in-house dental plan for all patients. Understanding that budget can ... that gives patients a number of perks, including discounts on many valuable dental ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a nationally ... of a new eating disorder treatment center location in Palm Beach Gardens, Florida.  The ... adolescents, both males and females ages 10 and older with eating disorders, including ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):